Ondokuzmayis University, Kurupelit Kampüsü, Samsun, Turkey.
BMC Infect Dis. 2012 Feb 16;12:42. doi: 10.1186/1471-2334-12-42.
Recent evidence indicates that Gram-negative bacterial pathogens, the most common of which are Pseudomonas spp., Enterobacteriaceae, and Acinetobacter baumannii, are frequent causes of hospital-acquired infections. This study aims to evaluate the in vitro activity of doripenem and comparator carbapenem antibiotics against Gram-negative clinical isolates collected from COMParative Activity of Carbapenem Testing (COMPACT) study centres in Turkey.
Ten centres in Turkey were invited to submit Pseudomonas aeruginosa, Enterobacteriaceae, and other Gram-negative isolates from intensive care unit (ICU)/non-ICU patients with complicated intra-abdominal infections, bloodstream infections, or nosocomial pneumonia, including ventilator-associated pneumonia, between May and October 2008. Susceptibility was determined by each centre using E-test. A central laboratory performed species confirmation as well as limited susceptibility and quality-control testing.
Five hundred and ninety six isolates were collected. MIC90 values for doripenem, meropenem, and imipenem, respectively, were 32, ≥ 64, and ≥ 64 mg/L against Pseudomonas spp.; 0.12, 0.12, and 0.5 mg/L against Enterobacteriaceae; and ≥ 64 mg/L for each against other Gram-negative isolates. In determining the susceptibility of hospital isolates of selected Gram-negative pathogens to doripenem, imipenem, and meropenem, we found that against all pathogens combined, the MIC90 for ICU compared with non-ICU isolates was higher.
Doripenem showed similar or slightly better activity than meropenem and better activity than imipenem against the Gram-negative pathogens collected in Turkey.
最近的证据表明，革兰氏阴性细菌病原体是最常见的病原体，其中包括铜绿假单胞菌、肠杆菌科和鲍曼不动杆菌，是医院获得性感染的常见原因。本研究旨在评估多利培南和比较碳青霉烯类抗生素对从土耳其比较碳青霉烯类抗生素测试（COMPACT）研究中心收集的革兰氏阴性临床分离株的体外活性。
邀请土耳其的 10 个中心提交来自 ICU/非 ICU 患者的复杂性腹腔内感染、血流感染或医院获得性肺炎（包括呼吸机相关性肺炎）的铜绿假单胞菌、肠杆菌科和其他革兰氏阴性分离株，时间为 2008 年 5 月至 10 月。各中心使用 E 试验法测定药敏性。中央实验室进行种属确认以及有限的药敏性和质量控制检测。
共收集了 596 株分离株。多利培南、美罗培南和亚胺培南的 MIC90 值分别为 32、≥64 和≥64mg/L，针对铜绿假单胞菌；0.12、0.12 和 0.5mg/L，针对肠杆菌科；其他革兰氏阴性分离株均为≥64mg/L。在确定选定革兰氏阴性病原体的医院分离株对多利培南、亚胺培南和美罗培南的敏感性时，我们发现，对于所有病原体，与非 ICU 分离株相比，ICU 分离株的 MIC90 值更高。
多利培南对革兰氏阴性病原体的活性与美罗培南相似或略优，优于亚胺培南。
